ADVANCED COURSES & SEMINARS
Rare brain cancers, Rare endocrine cancers, Rare gastro-intestinal cancers, Rare genito-urinary cancers, Rare gynaecological cancers, Rare head and neck cancers, Rare skin/eye melanoma, Rare thoracic cancers, Rare tumors, Sarcoma
*Third party registration should be used if you are requesting an individual registration for someone who is not you.
Please note that website registration under your name will be needed before registering someone else to this event.
Chairs: J.Y. Blay, FR - P.G. Casali, IT - R.A. Stahel, CH
The “ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is an educational effort, on an annual basis, conceived to strengthen the education of medical professionals willing to devote their career to rare cancers.
Despite being rare as single entities, rare adult solid cancers account for as many as 15% of all new cancer cases, thus being the main group within rare cancers in general. The RARECARE project’s definition and list of 10 “families” of rare adult solid cancers, have been fundamental in shaping the sessions of this course:
• Rare skin cancers & non-cutaneous melanoma
• Rare thoracic tumors
• Rare female genital cancers
• Neuroendocrine tumors
• Endocrine gland tumors
• Digestive rare cancers
• Rare urological and male genital tumors
• Central nervous system neoplasms
• Head & neck cancers
Since ‘networking’ and ‘multidisciplinarity’ are the two keywords to improve quality of care of rare cancers, ESO has decided to develop the programme of this course in collaboration with all the European initiatives in this field and to give its contribution to tackle the rare cancer issue. The “4th ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers” is conceived in the context of, and supported by the Joint Action on Rare Cancers of the European Union (JARC), a project coordinated by the Istituto Nazionale Tumori, Milan, and EURACAN, the European Reference Network on rare adult solid cancers. The Faculty has been largely selected from EURACAN, also with the aim of letting this educational effort closely interact with its networking activities and to help share the best knowledge and updates on these cancers.
The optimal management of rare adult solid cancers poses specific diagnostic and therapeutic challenges, which will be debated and addressed during the course through close interaction between opinion leaders and the participants. The sessions are designed to address the needs of oncologists wanting an update on the advancements in the clinical and research settings.
ESO is also pleased to help with the organization of the 3rd Rare Cancers Europe (RCE) training course for advocacy groups, which will be held in parallel sessions, with the aim to reinforce the relationship and exchange between physicians and patients representatives.
|The course is an ESO-ESMO-RCE joint event|
|Held in collaboration with||In the framework of|
M. Angi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
E. Baudin, Institut Gustave Roussy, Villejuif, FR
S. Bielack, Klinikum Stuttgart Olgahospital, Stuttgart, DE
J.Y. Blay, Centre Léon Bérard, Lyon, FR
P. Bruzzi, Istituto Nazionale Ricerca Cancro, Genoa, IT
P.G. Casali, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Cavalieri, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
F. De Braud, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A.P. Dei Tos, Azienda ULSS9, Treviso, IT
C. De La Fouchardière, Centre Léon Bérard, Lyon, FR
F. De Lorenzo, European Cancer Patient Coalition, Brussels, BE
M. Deraco, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Droz Dit Busset, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
H. Duffau, Hopital Gui de Chauliac, Montpellier, FR
J.G. Eriksen, Aarhus University Hospital, Aarhus, DK
N. Fazio, Istituto Europeo di Oncologia, Milan, IT
A.M. Frezza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Garassino, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
J.A. Gietema, University Medical Center, Groningen, NL
R. Glynne-Jones, Mount Vernon Centre for Cancer Treatment, London, UK
S. Grisanti, A.O. Spedali Civili, Brescia, IT
A. Gronchi, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
A. Idbaih, APHP Hopital de la Salpetriere, Paris, FR
E. Kapiteijn, Leiden University Medical Center, NL
C. Lebbé, Hopital St. Louis, Paris, FR
L. Licitra, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
L. Locati, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Newbold, The Royal Marsden NHS Foundation Trust, London, UK
N. Nicolai, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
M. Niger, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
K. Oliver, International Brain Tumour Alliance, Tadworth, UK
F. Peccatori, European School of Oncology, Milan, IT
C. Piazza, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
S. Piperno-Neumann, Institut Curie, Paris, FR
I. Ray-Coquard, Centre Léon Bérard, Lyon, FR
M. Seckl, Hammersmith Campus, London, UK
R. Soffietti, AOU San Giovanni Battista, Torino, IT
S. Stacchiotti, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
R.A. Stahel, Cancer Center University Hospital, Zurich, CH
A. Trama, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
L. Wyrwicz, Marie Curie Memorial Cancer Center, Warsaw, PL
- Medical degree
- Specialization/residency in medical oncology, radiation oncology, surgical oncology or equivalent
Update on the latest clinical development with a background perspective on the state-of-the-art and evidence based practice.
MZ CONGRESSI s.r.l.
ID no. 966
Via Carlo Farini, 81
European School of Oncology
Rare Tumours Programme
c/o Fondazione IRCCS Istituto Nazionale dei Tumori
Via G. Venezian, 1
20133 Milano - Italy
Fax +39 0223902531
Fondazione Cariplo Conference Center
Via Romagnosi, 8
Application for CME recognition will be submitted to the European Accreditation Council for Continuing Medical Education (EACCME) and to the Italian CME accreditation system.
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising Secretariat.
The badge is the only official evidence of registration and should be worn at all times during the event.
The organisers bear no responsibility for untoward events in relation to the participation during the Course. Participants are advised to take out their own personal and travel insurance.
The official language will be English. No translation will be provided.
|Early registration:||31 October 2019|
|Save event date:||29 November 2019|
|Early registration by:||insert the date|
|Late registration by:||insert the date|
|Onsite registration from:||insert the date|
TRAVEL GRANTS (FOR PHYSICIANS ONLY)
Travel grants are made available on a competitive basis thanks to the support of Rare Cancers Europe. Priority will be given to younger candidates (under the age of 40) and physicians from low/middle income Countries as defined by The World Bank.
Travel grant recipients will receive a set amount to contribute to their travel and accommodation expenses, whilst registration will be processed directly by the organisers.
To submit the Travel Grant application please complete the online form (available at the bottom of this page) and upload your Curriculum vitae and motivation letter by 1st October.
All applicants will be contacted by 15th October. Unselected applicants will still be able to register with the early rate fee (deadline: 31st October).
The following amount will be refunded by bank transfer after the Course:
Participants coming from Europe, Middle East and North Africa: € 700
Participants coming from other regions and overseas: € 1000
Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme.
Interested oncologists should register online (at the top of this page).
(From 1 November)
|| EUR 250
|| EUR 300
|Club ESO and ESMO Members|| EUR 200
Rates are quoted in Euro and include VAT.
CANCELLATION OF REGISTRATION OR REPLACEMENT
Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee less handling charges of EUR 80 will be refunded after the event, provided that the cancellation is received by ESO before 2 November. Replacements will be possible till 2 November.
PATIENT ADVOCATE REGISTRATION AND TRAVEL GRANT
Please contact RARE CANCERS EUROPE.
For information: email@example.com
|10:30||Registration and coffee entry
|11:00||Welcome from ESO and ESMO
F. Peccatori IT - R.A. Stahel, CH
|INTRODUCTION (plenary session with PAGs)|
|11:20||The problem of rare cancers
P.G. Casali, IT
|11:40||Networking on rare cancers
A.M. Frezza, IT
|12:00||What can we do politically?
F. de Lorenzo, IT - K. Oliver, UK
|12:20||The epidemiological enigma of rare cancers
A. Trama, IT
|12:40||Collaborative clinical registries in rare cancers: the ETOP-NTRK registry
R. Stahel, CH
|UPDATE ON CNS TUMORS
Moderators: R. Soffietti, IT - A. Idbaih, FR
R. Soffietti, IT
|14:20||Rare CNS tumors
A. Idbaih, FR
|14:40||Molecular approaches to CNS tumors
R. Soffietti, IT
|15:00||New developments in surgery of CNS tumors
H. Duffau, FR
|UPDATE ON RARE THORACIC CANCERS
Moderators: M. Garassino, IT - R.A. Stahel, CH
R.A. Stahel, CH
M. Garassino, IT
|UPDATE ON RARE FEMALE GENITAL CANCERS
Moderators: M. Seckl, UK - F. Peccatori, IT
|17:30||Non-epithelial ovarian tumors
I. Ray-Coquard, FR
M. Seckl, UK
|8:30||The scope of pathologic diagnosis in rare cancers:
which molecular profiling should be provided today?
A.P. Dei Tos, IT
|UPDATE ON RARE SKIN TUMORS & UVEAL MELANOMA Moderators: S. Piperno-Neumann, FR - E. Kapiteijn, NL|
|9:00||Merkel cell carcinoma
C. Lebbé, FR
|9:20||Cutaneous adnexal malignancies
S. Cavalieri, IT
M. Angi, IT
|Update on HEAD & NECK CANCERS
Moderators: J.G. Eriksen, DK - L. Licitra, IT
|11:00||Laryngeal & hypopharyngeal carcinoma
L. Licitra, IT
J.G. Eriksen, DK
|11:40||Nasopharyngeal carcinoma & sinonasal cancers
L. Licitra, IT
|12:00||Salivary gland tumors
L. Locati, IT
|12:20||Oral cavity tumors
C. Piazza, IT
|UPDATE ON SARCOMAS
Moderators: P.G. Casali, IT - A. Gronchi, IT
|14:00||Adult soft tissue sarcomas (STS)
P.G. Casali, IT
J.Y. Blay, FR
|14:40||Preoperative chemo-radiation therapy in STS
A. Gronchi, IT
|15:00||Rare bone sarcomas
S. Stacchiotti, IT
|15:20||Ewing sarcoma and Osteosarcoma
S. Bielack, DE
|16:40||Being histologically agnostic in rare cancers
J.Y. Blay, FR
|UPDATE ON ENDOCRINE GLAND TUMORS
Moderators: C. De La Fouchardière, FR - L. Licitra, IT
S. Grisanti, IT
K. Newbold, UK
|8:30||Quality of evidence in rare cancers
|UPDATE ON DIGESTIVE RARE CANCERS
Moderators: L. Wyrwicz, PL - F. de Braud, IT
M. Niger, IT
R. Glynne-Jones, UK
|9:40||Peritoneal mesothelioma & pseudomyxoma peritonei
M. Deraco, IT
|UPDATE ON RARE UROGENITAL CANCERS
Moderators: J.A. Gietema, NL - N. Nicolai, IT
J.A. Gietema, NL
|UPDATE ON NEUROENDOCRINE TUMORS
Moderators: M. Caplin, UK - F. De Braud, IT
|11:40||Thoracic neuroendocrine tumors
E. Baudin, FR
|12:00||Gastroenteropancreatic neuroendocrine tumors
N. Fazio, IT
|12:20||Surgery in neuroendocrine tumors
M. Droz dit Busset, IT